# Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Source: https://onco.cc/trials/nct05692999/  
OnCo record `nct05692999` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study is a phase 3, randomised interventional study registered as NCT05692999 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 1166 participants, started 2023-03-20 and due to reach its primary completion in 2029-01. Interventions recorded: Pembrolizumab 200 mg Q6W; Pemetrexed 500 mg/m^2 Q3W; Pembrolizumab 200 mg Q3W or 400 mg Q6W. Conditions listed: Metastatic Non-squamous Lung Cancer. Primary outcome: Overall survival. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC)". Sites: Belgium, France, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: Pulse
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05692999
- Phase: 3
- Setting: Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 1166

## Sources

- ClinicalTrials.gov NCT05692999: https://clinicaltrials.gov/study/NCT05692999

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05692999.json